gabapentin has been researched along with Diabetic Nephropathies in 8 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To characterize and compare healthcare resource utilization and costs among patients with painful diabetic peripheral neuropathy (pDPN) newly prescribed pregabalin or gabapentin in a real-world clinical setting." | 7.78 | Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy. ( Harnett, J; Mardekian, J; Udall, M, 2012) |
| "Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy." | 7.76 | Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain. ( Cooke, I; Goodchild, CS; Kolosov, A, 2010) |
| "Gabapentin (GBP) is a drug which is frequently used in diabetic neuropathy." | 5.35 | Gabapentin-induced rhabdomyolysis in a patient with diabetic neuropathy. ( Bilgir, F; Bilgir, O; Calan, M; Kebapçilar, L; Sari, I; Yildiz, Y; Yüksel, A, 2009) |
| "To characterize and compare healthcare resource utilization and costs among patients with painful diabetic peripheral neuropathy (pDPN) newly prescribed pregabalin or gabapentin in a real-world clinical setting." | 3.78 | Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy. ( Harnett, J; Mardekian, J; Udall, M, 2012) |
| "Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy." | 3.76 | Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain. ( Cooke, I; Goodchild, CS; Kolosov, A, 2010) |
| " With 2-L exchanges every 2 hours, we document an apparent elimination half-life of 41." | 1.46 | Treatment of Gabapentin Toxicity With Peritoneal Dialysis: Assessment of Gabapentin Clearance. ( Edwards, JC; Ibrahim, H; Oman, Z; Schuelke, M, 2017) |
| "Gabapentin (GBP) is a drug which is frequently used in diabetic neuropathy." | 1.35 | Gabapentin-induced rhabdomyolysis in a patient with diabetic neuropathy. ( Bilgir, F; Bilgir, O; Calan, M; Kebapçilar, L; Sari, I; Yildiz, Y; Yüksel, A, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ibrahim, H | 1 |
| Oman, Z | 1 |
| Schuelke, M | 1 |
| Edwards, JC | 1 |
| Sicras, A | 1 |
| Rejas, J | 1 |
| Navarro, R | 1 |
| Planas, A | 1 |
| Bilgir, O | 1 |
| Calan, M | 1 |
| Bilgir, F | 1 |
| Kebapçilar, L | 1 |
| Yüksel, A | 1 |
| Yildiz, Y | 1 |
| Sari, I | 1 |
| Chen, DT | 1 |
| Wynia, MK | 1 |
| Moloney, RM | 1 |
| Alexander, GC | 1 |
| Kolosov, A | 1 |
| Goodchild, CS | 1 |
| Cooke, I | 1 |
| Udall, M | 1 |
| Harnett, J | 1 |
| Mardekian, J | 1 |
| Hosseini-Zare, MS | 1 |
| Dashti-Khavidaki, S | 1 |
| Mahdavi-Mazdeh, M | 1 |
| Ahmadi, F | 1 |
| Akrami, S | 1 |
| Tesfaye, S | 1 |
| Selvarajah, D | 1 |
8 other studies available for gabapentin and Diabetic Nephropathies
| Article | Year |
|---|---|
Treatment of Gabapentin Toxicity With Peritoneal Dialysis: Assessment of Gabapentin Clearance.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Nephropathies; Diabetic Neuropathies; Fema | 2017 |
Adding pregabalin or gabapentin for the management of community-treated patients with painful diabetic peripheral neuropathy: a comparative cost analysis.
Topics: Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Diabetic Nephropathies; Drug Costs; Female; Gabape | 2013 |
Gabapentin-induced rhabdomyolysis in a patient with diabetic neuropathy.
Topics: Amines; Anticonvulsants; Creatinine; Cyclohexanecarboxylic Acids; Diabetic Nephropathies; Dose-Respo | 2009 |
U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Data Collection; Diabetic Nephropathies; Drug Appro | 2009 |
Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain.
Topics: Amines; Analgesics, Opioid; Animals; Carrageenan; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Ex | 2010 |
Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Databases, Factual; Diabetic Nephropathies; F | 2012 |
Peripheral neuropathy response to erythropoietin in type 2 diabetic patients with mild to moderate renal failure.
Topics: Aged; Aged, 80 and over; Amines; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type 2; Diabetic Ne | 2012 |
Morphine, gabapentin, or their combination for neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Nephropathies; Drug Therapy, Combination; | 2005 |